08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

ATx08-001: Phase II data

A double-blind, U.S. Phase II trial in 61 patients showed that twice-daily 2.5 and 7.5 mg oral ATx08-001 each met the primary endpoint of significantly reducing mean pain intensity scores from baseline to week 1...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Aestus Therapeutics, Astellas deal

Astellas' Prosidion Ltd. subsidiary granted Aestus exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial of the glycogen phosphorylase inhibitor in post-herpetic neuralgia (PHN) by the...
00:58 , Sep 20, 2011 |  BC Extra  |  Company News

Prosidion, Aestus partner for pain compound

Prosidion Ltd. , a subsidiary of Astellas Pharma Inc. (Tokyo:4503), granted Aestus Therapeutics Inc. (North Brunswick, N.J.) exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Clinical News

ATx08-001: Phase II started

Aestus began a double-blind, placebo-controlled Phase II trial to evaluate low- and high-doses of oral ATx08-001 in about 60 patients. Aestus has exclusive, worldwide rights to ATx08-001 from Astellas (see BioCentury, July 5, 2010). Aestus...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Aestus Therapeutics, Astellas deal

Astellas granted Aestus an exclusive, worldwide license to FK614 . Aestus, which renamed the compound ATx08-001 , plans to start a Phase II trial of the peroxisome proliferation activated receptor (PPAR) gamma agonist to treat...
08:00 , Mar 8, 2004 |  BioCentury  |  Strategy

The Fuji-Yama merger

The Fuji-Yama merger...